Cardiovascular Disease (CVD)

AHA: Mavacamten May Treat Hypertrophic Cardiomyopathy

Publish Date November 24, 2020

Improvements in cardiac structure, function seen at 30 weeks of treatment with mavacamten versus placebo.

MI, ASCVD Risk Higher in Older Adults With Elevated LDL-C

Publish Date November 20, 2020

And LDL cholesterol-lowering therapies are effective for reducing cardiovascular events in older adults

Sotagliflozin Reduces Risk for Adverse CV Events in Diabetic Kidney Disease

Publish Date November 18, 2020

Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.

Patients With Diabetes and CVD on Empagliflozin Have Fewer CV, Renal Events

Publish Date November 5, 2020

Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.

Markers to Predict CI-AKI in Patients With ACS Undergoing Coronary Angiography

Publish Date November 5, 2020

BNP or NT-proBNP may represent effective markers for the prediction of contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.

Incident CVD Up With Sugary, Artificially Sweetened Drinks

Publish Date October 30, 2020

Risks for first incident CVD increased for higher consumers of sugary drinks, ASBs versus nonconsumers.

Most Couples Concordant for Cardiovascular Risk

Publish Date October 29, 2020

In 79% of couples, both members are in nonideal category for cardiovascular health score.

Metabolic Surgery Linked to Reduced Risk for MACE After MI

Publish Date October 28, 2020

Risk for death, new MI, heart failure lower with metabolic surgery in obese patients with previous MI.

Polypharmacy Common in Seniors With Heart Failure

Publish Date October 21, 2020

With increasing number of medications, more rapid increase seen in number of noncardiovascular meds.

MACE Up for High-Risk Patients After Noncardiac Surgery

Publish Date October 20, 2020

Incidence of MACE 20.6% within 365 days in patients at increased CV risk.